PPGN Stock Overview
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide.
PolyPeptide Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF72.45|
|52 Week High||CHF147.40|
|52 Week Low||CHF60.55|
|1 Month Change||-18.32%|
|3 Month Change||-6.88%|
|1 Year Change||-7.53%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-7.35%|
Recent News & Updates
Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Despite posting some strong earnings, the market for PolyPeptide Group AG's ( VTX:PPGN ) stock hasn't moved much. Our...
|PPGN||CH Life Sciences||CH Market|
Return vs Industry: PPGN exceeded the Swiss Life Sciences industry which returned -8.7% over the past year.
Return vs Market: PPGN underperformed the Swiss Market which returned -2.4% over the past year.
|PPGN Average Weekly Movement||8.3%|
|Life Sciences Industry Average Movement||7.1%|
|Market Average Movement||5.0%|
|10% most volatile stocks in CH Market||9.0%|
|10% least volatile stocks in CH Market||2.5%|
Stable Share Price: PPGN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PPGN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
|1952||1,101||Raymond De Vre||https://www.polypeptide.com|
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies.
PolyPeptide Group Fundamentals Summary
|PPGN fundamental statistics|
Is PPGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PPGN income statement (TTM)|
|Cost of Revenue||€182.43m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||1.43|
|Net Profit Margin||16.68%|
How did PPGN perform over the long term?See historical performance and comparison
0.4%Current Dividend Yield
Is PolyPeptide Group undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PPGN (CHF72.45) is trading above our estimate of fair value (CHF25.95)
Significantly Below Fair Value: PPGN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PPGN is poor value based on its PE Ratio (49.2x) compared to the Swiss Life Sciences industry average (46.4x).
PE vs Market: PPGN is poor value based on its PE Ratio (49.2x) compared to the Swiss market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: PPGN is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: PPGN is overvalued based on its PB Ratio (5.5x) compared to the CH Life Sciences industry average (4.2x).
How is PolyPeptide Group forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PPGN's forecast earnings growth (15.3% per year) is above the savings rate (-0.3%).
Earnings vs Market: PPGN's earnings (15.3% per year) are forecast to grow faster than the Swiss market (6% per year).
High Growth Earnings: PPGN's earnings are forecast to grow, but not significantly.
Revenue vs Market: PPGN's revenue (12.4% per year) is forecast to grow faster than the Swiss market (4.3% per year).
High Growth Revenue: PPGN's revenue (12.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PPGN's Return on Equity is forecast to be low in 3 years time (14.8%).
How has PolyPeptide Group performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: PPGN has a high level of non-cash earnings.
Growing Profit Margin: PPGN's current net profit margins (16.7%) are higher than last year (14%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PPGN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare PPGN's past year earnings growth to its 5-year average.
Earnings vs Industry: PPGN earnings growth over the past year (50.8%) underperformed the Life Sciences industry 50.8%.
Return on Equity
High ROE: PPGN's Return on Equity (11.2%) is considered low.
How is PolyPeptide Group's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PPGN's short term assets (€331.6M) exceed its short term liabilities (€104.0M).
Long Term Liabilities: PPGN's short term assets (€331.6M) exceed its long term liabilities (€69.9M).
Debt to Equity History and Analysis
Debt Level: PPGN has more cash than its total debt.
Reducing Debt: Insufficient data to determine if PPGN's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: PPGN's debt is well covered by operating cash flow (501%).
Interest Coverage: PPGN's interest payments on its debt are well covered by EBIT (22.8x coverage).
What is PolyPeptide Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PPGN's dividend (0.41%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.88%).
High Dividend: PPGN's dividend (0.41%) is low compared to the top 25% of dividend payers in the Swiss market (3.91%).
Stability and Growth of Payments
Stable Dividend: PPGN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: PPGN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: PPGN is not paying a notable dividend for the Swiss market.
Cash Payout to Shareholders
Cash Flow Coverage: PPGN is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raymond De Vre (53 yo)
Dr. Raymond De Vré, Ph D served as Senior Vice President and Head Biologics at Dr. Reddy’s Laboratories Ltd. since June 01, 2018 until 2021, a division that focuses on the development of biosimilar molecul...
Experienced Management: PPGN's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Experienced Board: PPGN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PolyPeptide Group AG's employee growth, exchange listings and data sources
- Name: PolyPeptide Group AG
- Ticker: PPGN
- Exchange: SWX
- Founded: 1952
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF2.398b
- Shares outstanding: 33.10m
- Website: https://www.polypeptide.com
Number of Employees
- PolyPeptide Group AG
- Dammstrasse 19
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.